Needham lowered the firm’s price target on Neurocrine (NBIX) to $185 from $187 and keeps a Buy rating on the shares. The company guided to strong double-digit Ingrezza growth, in line with consensus of $2.72B, and expressed optimism around Crenessity’s growth trajectory in 2026, the analyst tells investors in a research note. The pipeline also remains well positioned, with the potential to deliver one new medicine every two years and two Phase 3 programs currently underway, the firm adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $190 from $195 at BofA
- Neurocrine price target raised to $151 from $149 at Wedbush
- Neurocrine price target lowered to $173 from $175 at Morgan Stanley
- Reaffirming Buy: Solid Core Franchise Execution and Underappreciated Pipeline Upside Support Mid-$150s Valuation
- Neurocrine Biosciences: Durable Ingrezza Franchise and Emerging Crenessity Uptake Support Buy Rating and $190 Price Target